Drugs / Microgynon
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT07784894 | Aug → Nov 2026 expected | tuberculosis | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1 | NCT06354257 | Apr → Jul 2024 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT05153564 | Dec 2021 → Aug 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03745144 | Jan 2019 → Sep 2022 | relapsing-remitting multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT03210246 | Jul 2017 → Jun 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02845219 | Jul → Dec 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02159326 | Jun 2014 → Mar 2015 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01941615 | Nov 2013 → Jan 2014 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT01896726 | Jul → Oct 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01615354 | Jul 2012 → Jan 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02385448 Comparator | Feb 2015 → Feb 2017 | endometriosis | The University of Hong Kong | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Microgynon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03210246 ↗ |
| Route | Oral | “Multiple oral doses” NCT01615354 ↗ |